Last updated: September 5, 2026
Procarbazine hydrochloride is a mature, low-volume oral oncology drug with limited patent protection, no biosimilar exposure, and a market shaped more by manufacturing continuity than by intellectual property. The originator product, Matulane, is used primarily in combination regimens for Hodgkin lymphoma. Generic competition has reduced long-term brand value, but the product can experience price volatility because relatively few manufacturers serve a specialized market.
Standalone revenue data are not publicly disclosed for Matulane or generic procarbazine hydrochloride. The commercial outlook is therefore best assessed through prescription demand, treatment guidelines, supplier concentration, shortage risk, and the absence of meaningful regulatory exclusivity.
What is procarbazine hydrochloride used for?
Procarbazine hydrochloride is an oral methylhydrazine derivative classified as an alkylating-type antineoplastic agent. The FDA-approved indication is combination treatment for Hodgkin lymphoma, particularly in regimens that historically include mechlorethamine, vincristine, procarbazine, and prednisone, known as MOPP therapy.[1]
| Product attribute |
Data |
| Active ingredient |
Procarbazine hydrochloride |
| Dosage form |
Oral capsule |
| Common strength |
50 mg |
| Originator brand |
Matulane |
| FDA application |
NDA 012123 |
| Principal approved use |
Combination treatment of Hodgkin lymphoma |
| Common clinical role |
Component of multi-agent chemotherapy |
| Drug class |
Antineoplastic methylhydrazine derivative |
| Biosimilar applicability |
None |
| Main commercial market |
Specialty oncology and hospital-linked dispensing |
Procarbazine is also used in some central nervous system tumor regimens, including combinations for gliomas, although those uses are generally governed by clinical practice and institutional protocols rather than the original Hodgkin lymphoma labeling.[2]
Demand is structurally limited because procarbazine is not a broad-use oncology medicine. It is administered to selected patients in defined chemotherapy protocols. Many Hodgkin lymphoma patients now receive regimens that do not contain procarbazine, including ABVD, A+AVD, and other modern treatment approaches.[3]
What is the FDA regulatory status of procarbazine hydrochloride?
Matulane is an FDA-approved prescription drug marketed as a 50 mg capsule. Procarbazine hydrochloride is not a biologic and does not require a biosimilar approval pathway. Generic versions are approved through abbreviated new drug applications, or ANDAs, that rely on the reference product for safety and efficacy.
The commercial regulatory structure is mature:
| Regulatory factor |
Assessment |
| New chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
No current relevant exclusivity identified |
| Pediatric exclusivity |
No current relevant period identified |
| Generic pathway |
ANDA |
| Biosimilar pathway |
Not applicable |
| Brand approval |
Matulane, NDA 012123 |
| Current clinical requirement |
Prescription oncology use |
| FDA market risk |
Manufacturing and supply continuity rather than approval exclusivity |
The principal FDA-related commercial issue is availability. A small oncology product can remain vulnerable to supply interruptions even when multiple ANDAs exist because approved suppliers may not actively manufacture the product at commercial scale.
What patents protect procarbazine hydrochloride?
The original composition and product patents for procarbazine hydrochloride are long expired. No active foundational patent estate is expected to block generic manufacture.
What is the Orange Book status of Matulane?
Matulane’s commercial position does not appear to depend on a significant active Orange Book patent portfolio. The FDA Orange Book is the controlling source for listed patents and exclusivity associated with approved drug products.[4]
| Patent category |
Current commercial relevance |
| Original compound patent |
Expired |
| Original formulation patent |
Expired or no longer commercially blocking |
| Method-of-use patents |
No material blocking estate identified |
| Manufacturing patents |
Potentially relevant at the process level, but not expected to prevent ordinary generic entry |
| Orange Book-listed patents |
No significant active patent barrier identified |
| Patent term extension |
No meaningful current impact |
A generic manufacturer could still face process patents, supplier know-how, controlled-substance handling requirements, or trade-secret restrictions. Those rights would not ordinarily create the same market exclusion as an unexpired composition-of-matter or formulation patent.
When did procarbazine lose exclusivity?
Procarbazine lost meaningful small-molecule exclusivity decades ago. The product was introduced in the 1960s, and its original patent and regulatory exclusivity periods have expired. Current competition therefore depends on ANDA approval, manufacturing economics, procurement contracts, and supply reliability rather than on patent expiration timing.
How many patents cover procarbazine hydrochloride?
No meaningful number of active, blocking patents can be assigned to procarbazine hydrochloride as a marketed drug based on the public regulatory record. Historical patents may appear in patent databases for synthesis, formulations, combinations, or specific therapeutic uses. Those documents do not necessarily create enforceable market exclusivity today.
The patent estate is weak compared with newer oncology products that rely on composition, crystalline-form, dosage, formulation, biomarker, and method-of-use patents.
| Patent-estate dimension |
Procarbazine assessment |
| Composition-of-matter protection |
Expired |
| Salt protection |
Commercially expired or nonblocking |
| Capsule formulation |
Limited practical value |
| Combination therapy claims |
Narrow and vulnerable to noninfringement or invalidity arguments |
| Process patents |
Possible, but supplier-specific |
| Patent litigation leverage |
Low |
| Generic launch barrier |
Low from an IP perspective |
Which companies are challenging the procarbazine market?
The market is challenged by generic manufacturers rather than by a high-profile Paragraph IV campaign. Procarbazine has been generic for many years, so the principal competitive questions are whether a manufacturer maintains an active ANDA and whether it can supply the product consistently.
Publicly visible competition has historically included the Matulane brand and generic oncology suppliers operating through hospital, specialty-pharmacy, and wholesaler channels. Manufacturer participation can change over time as companies discontinue low-volume products or consolidate oncology portfolios.
Are there Paragraph IV challenges to Matulane?
Paragraph IV litigation is not the central commercial issue for procarbazine. The product’s foundational exclusivity has expired, and generic entry has already occurred. No major current Paragraph IV dispute or settlement agreement is a defining feature of the market based on the public FDA and court record available through mid-2024.
The absence of major litigation reflects the economics of the product. A low-volume, mature oncology capsule generally offers limited incentive to finance costly patent litigation unless the brand maintains unusually high pricing or a new formulation creates a separate commercial opportunity.
What formulations are protected by procarbazine patents?
The marketed formulation is a conventional 50 mg oral capsule. There is no widely recognized active formulation patent that materially protects the market.
Potential technical barriers include:
- Stability of the active pharmaceutical ingredient.
- Control of degradation products.
- Capsule content uniformity.
- Packaging and light or moisture protection.
- Reproducible dissolution.
- Safe handling of a cytotoxic compound.
- Qualification of active pharmaceutical ingredient suppliers.
These requirements can raise the cost of entry without creating legal exclusivity. A manufacturer may need specialized containment systems and validated analytical methods, especially because oncology products are subject to strict quality controls.
What manufacturing and supply barriers affect procarbazine?
Manufacturing risk is more important than patent risk. Procarbazine is a low-volume product with a narrow clinical role. That combination can produce a fragile supply chain.
Why can a generic oncology drug remain expensive?
A generic price does not necessarily fall to commodity levels when:
- Annual demand is small.
- Few suppliers manufacture the product.
- Production requires dedicated containment or specialized personnel.
- Hospitals require reliable supply and cannot easily substitute the drug.
- The active ingredient has limited global production capacity.
- Wholesalers carry low inventory because of slow turnover.
- Quality or regulatory problems remove one supplier from the market.
The result can be a two-tier market. Contracted institutional buyers may obtain competitive prices, while smaller pharmacies or urgent purchasers may face materially higher acquisition costs.
FDA and ASHP shortage-monitoring resources are relevant because oncology shortages can arise from manufacturing interruptions, quality failures, raw-material constraints, or commercial discontinuation.[5,6]
What is the financial trajectory for procarbazine hydrochloride?
The financial trajectory is mature to declining in unit demand, with possible revenue resilience from pricing and supply scarcity. There is no publicly reported standalone revenue series for Matulane or generic procarbazine that would support a precise market-size or compound annual growth rate calculation.
| Financial driver |
Directional impact |
| Patient volume |
Flat to declining |
| Use in Hodgkin lymphoma |
Reduced by newer regimens |
| Use in glioma protocols |
Provides residual demand |
| Brand share |
Low relative to generic supply |
| Unit price |
Volatile; can rise during shortages |
| Gross margin |
Potentially attractive for efficient suppliers |
| Sales and marketing need |
Low |
| Manufacturing complexity |
Moderate relative to market size |
| Revenue visibility |
Limited |
| Long-term growth |
Weak |
What supports residual demand?
Procarbazine retains value in established treatment protocols, especially where clinicians use MOPP-like therapy or PCV-type regimens. Existing clinical familiarity, low acquisition volumes, and the absence of a direct replacement in every protocol support continued baseline demand.
What suppresses growth?
The drug faces several structural headwinds:
- Declining use of older Hodgkin lymphoma regimens.
- Availability of targeted and antibody-based oncology therapies.
- Greater use of PET-adapted and response-adapted treatment.
- Limited use outside defined protocols.
- Generic substitution.
- Low incentives for broad commercial investment.
- Potential supplier exits.
The most likely revenue pattern is a small, stable or gradually shrinking underlying market interrupted by periods of price expansion when supply becomes constrained.
How does procarbazine compare with competing Hodgkin lymphoma drugs?
Procarbazine is commercially weaker than newer agents but remains relevant in selected combinations.
| Drug or regimen |
Role in Hodgkin lymphoma |
Commercial position |
| Procarbazine |
Older combination component |
Mature generic, low growth |
| Dacarbazine |
Component of ABVD and related regimens |
Mature generic, broader use |
| Vinblastine |
Core chemotherapy agent |
Mature generic |
| Brentuximab vedotin |
Targeted antibody-drug conjugate |
Higher-value branded product |
| Pembrolizumab |
PD-1 immunotherapy |
High-value branded or patent-protected market |
| Nivolumab |
PD-1 immunotherapy |
High-value immuno-oncology product |
| Bendamustine |
Alternative chemotherapy in selected settings |
Generic and branded competition |
Procarbazine’s cost per dose is generally much lower than the cost of targeted therapies. Its commercial value lies in protocol necessity and supply reliability, not in premium clinical differentiation.
What patent litigation affects procarbazine hydrochloride?
No major active patent litigation is known to define the procarbazine market through mid-2024. The likely legal disputes are operational rather than exclusivity-driven:
- ANDA product liability.
- Manufacturing quality claims.
- Contract and supply disputes.
- Labeling or pharmacovigilance issues.
- Procurement disputes.
- Patent claims against a new formulation or manufacturing process.
A new extended-release, liquid, pediatric, or combination formulation could create a distinct patent opportunity. The conventional 50 mg capsule has limited room for durable exclusivity.
What generic launch risks exist for procarbazine?
A new generic entrant would face low patent risk but meaningful commercial risk.
Generic launch scenario
| Scenario |
Likely outcome |
| New ANDA enters a fully supplied market |
Price pressure and limited volume |
| Existing supplier exits |
Higher prices and greater share for remaining manufacturers |
| FDA quality action removes a supplier |
Temporary shortage and rapid price escalation |
| Brand retains dependable supply |
Matulane remains a niche premium option |
| Hospital contracting favors lowest cost |
Generic share increases |
| New formulation launches |
Possible differentiated pricing if clinically useful |
A launch is most attractive when supply is inadequate, rather than when normal generic competition is already intense. The addressable market is too small to support substantial promotional spending.
What is the geographic coverage of procarbazine?
Procarbazine is marketed in multiple countries, but product availability, brand names, approved indications, and supplier participation vary by jurisdiction. The United States remains an important reference market because of its oncology infrastructure and FDA-approved Matulane product.
Geographic commercial risks include:
- Country-specific shortage exposure.
- Dependence on imported active pharmaceutical ingredient.
- Different pharmacovigilance and packaging requirements.
- National reimbursement controls.
- Hospital tender pricing.
- Limited registration incentives in small markets.
A manufacturer with global regulatory registrations can reduce dependence on one market, but the underlying demand remains niche.
Is procarbazine hydrochloride a strong pharmaceutical investment?
Procarbazine is a defensive specialty-generic opportunity, not a high-growth pharmaceutical asset. Its investment case depends on supply scarcity, reliable manufacturing, and portfolio efficiency.
The strongest commercial thesis is a low-competition supplier with:
- An active ANDA.
- Reliable API access.
- Validated cytotoxic manufacturing capacity.
- Hospital and specialty-pharmacy distribution.
- The ability to maintain inventory.
- Low overhead for a mature product.
The weakest thesis is a high-cost entrant expecting rapid volume growth from a declining legacy regimen.
Key Takeaways
- Procarbazine hydrochloride is a mature generic oncology drug with low underlying growth.
- Matulane is the principal U.S. branded reference product, with FDA NDA 012123.
- Original patent and exclusivity rights have expired.
- No significant active Orange Book patent barrier is expected to block generic competition.
- No biosimilar pathway applies because procarbazine is a small-molecule drug.
- Supply reliability, not patent litigation, is the central market risk.
- Revenue data are not publicly disclosed on a reliable standalone basis.
- Demand is likely flat to declining, while pricing can rise during supply disruptions.
- Generic entry risk is legally low but commercially constrained by limited market size.
- The product can remain financially attractive for efficient suppliers despite weak growth.
FAQs About Procarbazine Hydrochloride
Is procarbazine hydrochloride still commercially available?
Yes. Procarbazine remains available as Matulane and through generic channels, although availability can vary by supplier and market.
Does procarbazine hydrochloride have an active composition patent?
No active foundational composition patent is expected to protect the marketed drug. Its original composition-related exclusivity expired decades ago.
Can a generic company launch procarbazine without patent litigation?
Yes, assuming FDA approval, manufacturing compliance, and commercial supply capability. The principal barriers are market size and production economics rather than a blocking composition patent.
Is procarbazine hydrochloride at risk from biosimilars?
No. Biosimilars apply to biologic products. Procarbazine is a conventional small-molecule chemical drug and competes through generic ANDA approvals.
What would increase the value of a procarbazine product?
A sustained shortage, reliable API access, hospital contracts, or a differentiated formulation could increase product value. A new formulation would need clinical or logistical advantages to justify development costs in a small market.
References
-
U.S. Food and Drug Administration. (n.d.). Matulane (procarbazine hydrochloride) capsules: Prescribing information. FDA.
-
National Cancer Institute. (n.d.). Procarbazine hydrochloride. NCI Drug Dictionary.
-
National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology: Hodgkin lymphoma. NCCN.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.
-
U.S. Food and Drug Administration. (2024). Drug shortages. FDA.
-
American Society of Health-System Pharmacists. (2024). ASHP drug shortages database. ASHP.
